BeyondSpring Inc (BYSI)

NASDAQ
Currency in USD
3.110
-0.290(-8.53%)
Closed·
After Hours
3.100-0.010(-0.322%)
·
BYSI Scorecard
Full Analysis
RSI suggests the stock is in overbought territory
Unusual trading volume
Fair Value
Day's Range
2.7303.360
52 wk Range
0.9803.440
Key Statistics
Edit
Prev. Close
3.4
Open
3.36
Day's Range
2.73-3.36
52 wk Range
0.98-3.44
Volume
213.61K
Average Volume (3m)
40.16K
1-Year Change
9.51%
Book Value / Share
-0.7
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BYSI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

BeyondSpring Inc News & Analysis

Show more

BeyondSpring Inc Company Profile

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company’s lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Compare BYSI to Peers and Sector

Metrics to compare
BYSI
Peers
Sector
Relationship
P/E Ratio
−14.0x−6.0x−0.5x
PEG Ratio
−0.170.040.00
Price/Book
−4.4x4.1x2.6x
Price / LTM Sales
-3,360.9x3.0x
Upside (Analyst Target)
-198.8%51.5%
Fair Value Upside
Unlock5.5%9.4%Unlock

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.08 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

BYSI Income Statement

People Also Watch

3.700
SPWH
-2.12%
13.700
ETON
+0.66%
32.73
CYTK
+0.58%
128.12
BPMC
-0.09%
5.630
BTM
-6.63%

FAQ

What Is the BeyondSpring (BYSI) Stock Price Today?

The BeyondSpring stock price today is 3.11

What Stock Exchange Does BeyondSpring Trade On?

BeyondSpring is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for BeyondSpring?

The stock symbol for BeyondSpring is "BYSI."

What Is the BeyondSpring Market Cap?

As of today, BeyondSpring market cap is 125.38M.

What Is BeyondSpring's Earnings Per Share (TTM)?

The BeyondSpring EPS (TTM) is -0.22.

When Is the Next BeyondSpring Earnings Date?

BeyondSpring will release its next earnings report on Sep 05, 2025.

From a Technical Analysis Perspective, Is BYSI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has BeyondSpring Stock Split?

BeyondSpring has split 0 times.

How Many Employees Does BeyondSpring Have?

BeyondSpring has 40 employees.

What is the current trading status of BeyondSpring (BYSI)?

As of Jun 19, 2025, BeyondSpring (BYSI) is trading at a price of 3.11, with a previous close of 3.40. The stock has fluctuated within a day range of 2.73 to 3.36, while its 52-week range spans from 0.98 to 3.44.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.